Gilbert & Cook Inc. Increases Holdings in Pfizer Inc. (NYSE:PFE)
Gilbert & Cook Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 8,480 shares of the biopharmaceutical company’s stock after acquiring an additional 418 shares during the quarter. Gilbert & Cook Inc.’s holdings in Pfizer were worth $305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also made changes to their positions in PFE. Nuveen Asset Management LLC increased its position in shares of Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock valued at $1,563,256,000 after purchasing an additional 34,544,423 shares during the last quarter. Natixis purchased a new stake in shares of Pfizer during the 2nd quarter valued at $258,466,000. Invesco Ltd. increased its position in shares of Pfizer by 14.6% during the 2nd quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock valued at $914,857,000 after purchasing an additional 2,693,349 shares during the last quarter. DNB Asset Management AS increased its position in shares of Pfizer by 241.0% during the 3rd quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock valued at $134,164,000 after purchasing an additional 2,638,873 shares during the last quarter. Finally, Thoroughbred Financial Services LLC increased its position in shares of Pfizer by 4,297.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock valued at $265,668,000 after purchasing an additional 2,596,269 shares during the last quarter. 71.52% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Scott Gottlieb bought 3,000 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was acquired at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the purchase, the director now directly owns 3,000 shares in the company, valued at $104,160. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by company insiders.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.13. The company had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. The firm’s quarterly revenue was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.78 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.89%. Pfizer’s dividend payout ratio is currently 48.00%.
Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research note on Tuesday, October 1st. Credit Suisse Group reiterated a “hold” rating and set a $41.30 price target on shares of Pfizer in a research note on Wednesday. UBS Group reiterated a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research note on Monday, August 5th. Finally, Bank of America initiated coverage on Pfizer in a research note on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target for the company. Nine investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $44.02.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: What is a conference call?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.